

Building a Portfolio in FOP

- As a rare disease company, Blueprint was looking for a company with equal passion and dedication to rare disease patient communities. Ipsen's world-class global development capabilities and existing footprint in rare disease indications – including an ultra-rare bone disease, fibrodysplasia ossificans progressive (FOP) – made the company an attractive collaborator for Blueprint Medicines
- In addition to acquiring Clementia and its FOP asset palovarotene, Ipsen had access to the strong relationships with patient organizations. Those relationships, a patient registry, and natural history data demonstrated Ipsen's commitment to FOP and to bringing Blueprint's FOP asset to market for those who need it.
- Blueprint Medicines appreciated the smooth transition, Ipsen's engagement and how Ipsen makes it easy for Blueprint to focus on other candidates while Ipsen took full ownership of the FOP asset.

“We are confident that Ipsen, with its shared patient-centric culture, proven development capabilities and global commercial footprint, will fulfill our ambition of delivering palovarotene to patients worldwide.” – Clarissa Desjardins, CEO, Clementia

“Having experience in FOP, in rare diseases, recruiting and patient support that Ipsen already had in house and acquired through Clementia was very attractive and, in our view, increased the probability that our asset would get to the clinic.” – Michael Siracusa, Director of Corporate Development, Blueprint Medicines